CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Clinical trial NCT01191697 · COMPLETED
Trial details
- NCT number
- NCT01191697
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2021-12-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.